DelveInsight’s Age-related macular degeneration (AMD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Age-related macular degeneration (AMD) for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Age-related macular degeneration (AMD) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Age-related macular degeneration (AMD) till 2023.
Key Coverage and Benefits
• The report will help in developing business strategies by understanding the trends shaping and driving the global Age-related macular degeneration (AMD) market.
• Identifying patient populations in the global “Age-related macular degeneration (AMD) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Age-related macular degeneration (AMD) therapeutics in each of the markets covered.
• To understand the future market competition in the global Age-related macular degeneration (AMD) therapeutics market and Insightful review of the key market drivers and barriers.
Scope
• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2023.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
• It also provides Age-related macular degeneration (AMD) for United States, EU5 and Japan from 2013 and forecasted Market to 2023.
Note: This report requires 7-10 business days to complete.
'
Table of Contents
• Age-related macular degeneration (AMD) overview
• Pathophysiology
• Symptoms of disease
• Etiology of disease
• Diagnosis of disease
• Treatment of disease
• Overview of Marketed drugs
• Drug Description
• Mechanism of Action
• Pharmacokinetics Properties
• Marketed Details
• Patent Information
• Patent Exclusivity Expiry Assessment United States (US)
• Patents Details
• Historical and Forecasted sales of marketed molecules in the Global Age-related macular degeneration (AMD) Market
• Global Epidemiology of Age-related macular degeneration (AMD) Forecasted to 2023
• Global Market (2013-2015)
• Global Forecasted Market (2016-2023)
• Global Market by Geography
• Market of US (2013-2015)
• Forecasted Market of US (2016-2023)
• Market of Europe
• Market of Germany (2013-2015)
• Forecasted Market of Germany (2016-2023)
• Market of United Kingdom (2013-2015)
• Forecasted Market of United Kingdom (2016-2023)
• Market of France (2013-2015)
• Forecasted Market of France (2016-2023)
• Market of Italy (2013-2015)
• Forecasted Market of Italy (2016-2023)
• Market of Spain (2013-2015)
• Forecasted Market of Spain (2016-2023)
• Market of Japan (2013-2015)
• Forecasted Market of Japan (2016-2023)
• Market of ROW (2013-2015)
• Forecasted Market of ROW (2016-2023)
• Appendix
• Report Methodology
• Consulting Services
• Disclaimer
• Report Purchase Options
• About DelveInsight
List of Tables
• Table 1: Drug Description
• Table 2: Drug, Marketed Details United States (US)
• Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
• Table 4: Drug, Patent Details for US
• Table 5: Age-related macular degeneration (AMD) Drug Sales (USD Millions)
• Table 6: Global Epidemiology of Age-related macular degeneration (AMD) (2013-2023)
• Table 7: Age-related macular degeneration (AMD) Global Market (USD Millions), (2013-2015)
• Table 8: Age-related macular degeneration (AMD) Global Market (USD Millions), (2016-2023)
• Table 9: Age-related macular degeneration (AMD) US Market (USD Millions), (2013-2015)
• Table 10: Age-related macular degeneration (AMD) US Market (USD Millions), (2016-2023)
• Table 11: Age-related macular degeneration (AMD) Germany Market (USD Millions), (2013-2015)
• Table 12: Age-related macular degeneration (AMD) Germany Market (USD Millions), (2016-2023)
• Table 13: Age-related macular degeneration (AMD) United Kingdom Market (USD Millions), (2013-2015)
• Table 14: Age-related macular degeneration (AMD) United Kingdom Market (USD Millions), (2016-2023)
• Table 15: Age-related macular degeneration (AMD) France Market (USD Millions), (2013-2015)
• Table 16: Age-related macular degeneration (AMD) France Market (USD Millions), (2016-2023)
• Table 17: Age-related macular degeneration (AMD) Italy Market (USD Millions), (2013-2015)
• Table 18: Age-related macular degeneration (AMD) Italy Market (USD Millions), (2016-2023)
• Table 19: Age-related macular degeneration (AMD) Spain Market (USD Millions), (2013-2015)
• Table 20: Age-related macular degeneration (AMD) Spain Market (USD Millions), (2016-2023)
• Table 21: Age-related macular degeneration (AMD) Japan Market (USD Millions), (2013-2015)
• Table 22: Age-related macular degeneration (AMD) Japan Market (USD Millions), (2016-2023)
• Table 23: Age-related macular degeneration (AMD) ROW Market (USD Millions), (2013-2015)
• Table 24: Age-related macular degeneration (AMD) ROW Market (USD Millions), (2016-2023)
List of Figures
• Figure 1: Age-related macular degeneration (AMD) Drug Sales (USD Millions)
• Figure 2: Global Epidemiology of Age-related macular degeneration (AMD) (2013-2023)
• Figure 3: Age-related macular degeneration (AMD) Global Market (USD Millions), (2013-2015)
• Figure 4: Age-related macular degeneration (AMD) Global Market (USD Millions), (2016-2023)
• Figure 5: Age-related macular degeneration (AMD) US Market (USD Millions), (2013-2015)
• Figure 6: Age-related macular degeneration (AMD) US Market (USD Millions), (2016-2023)
• Figure 7: Age-related macular degeneration (AMD) Germany Market (USD Millions), (2013-2015)
• Figure 8: Age-related macular degeneration (AMD) Germany Market (USD Millions), (2016-2023)
• Figure 9: Age-related macular degeneration (AMD) United Kingdom Market (USD Millions), (2013-2015)
• Figure 10: Age-related macular degeneration (AMD) United Kingdom Market (USD Millions), (2016-2023)
• Figure 11: Age-related macular degeneration (AMD) France Market (USD Millions), (2013-2015)
• Figure 12: Age-related macular degeneration (AMD) France Market (USD Millions), (2016-2023)
• Figure 13: Age-related macular degeneration (AMD) Italy Market (USD Millions), (2013-2015)
• Figure 14: Age-related macular degeneration (AMD) Italy Market (USD Millions), (2016-2023)
• Figure 15: Age-related macular degeneration (AMD) Spain Market (USD Millions), (2013-2015)
• Figure 16: Age-related macular degeneration (AMD) Spain Market (USD Millions), (2016-2023)
• Figure 17: Age-related macular degeneration (AMD) Japan Market (USD Millions), (2013-2015)
• Figure 18: Age-related macular degeneration (AMD) Japan Market (USD Millions), (2015-2023)
• Figure 19: Age-related macular degeneration (AMD) ROW Market (USD Millions), (2013-2015)
• Figure 20: Age-related macular degeneration (AMD) ROW Market (USD Millions), (2016-2023)
• Genentech
• Archemix Corporation
• GlaxoSmithKline
• MorphoSys
• AnewPharma
• Tyrogenex
• Novartis
• Alcon
